Year Founded
2019
Ownership
Private
Employees
~100
Stage
Preclinical
Modalities
Bioengineered tissueOrgan-on-a-chipOther

Xilis General Information

Developing MicroOrganoSphere technology to enable rapid drug testing within 14 days for precision oncology. Platform maintains patient tumor microenvironment and captures response to immunotherapy.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Xilis's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Xilis Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Xilis's complete valuation and funding history, request access »

Xilis Investors

Pear VC
Investor Type: Venture Capital
Holding: Minority
SVB venture debt facility ($1.75M)
Investor Type: Venture Capital
Holding: Minority
Series A round ($70M raised)
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »